{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:13:09Z","timestamp":1792696389745,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,1,15]],"date-time":"2004-01-15T00:00:00Z","timestamp":1074124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,1,15]],"date-time":"2004-01-15T00:00:00Z","timestamp":1074124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2004,2,1]]},"DOI":"10.1038\/sj.gt.3302199","type":"journal-article","created":{"date-parts":[[2004,1,15]],"date-time":"2004-01-15T10:19:35Z","timestamp":1074161975000},"page":"408-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Gene therapy approaches for osteogenesis imperfecta"],"prefix":"10.1038","volume":"11","author":[{"given":"C","family":"Niyibizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PD","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,1,15]]},"reference":[{"key":"BF3302199_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s007760100072","volume":"6","author":"Y Chen","year":"2001","unstructured":"Chen Y . Orthopaedic applications of gene therapy. J Orth Sci 2001; 6: 199\u2013207.","journal-title":"J Orth Sci"},{"key":"BF3302199_CR2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2106\/00004623-199507000-00021","volume":"77","author":"CH Evans","year":"1995","unstructured":"Evans CH, Robbins PD . Possible orthopaedic application of gene therapy. J Bone Joint Surg Am 1995; 77: 1103\u20131114.","journal-title":"J Bone Joint Surg Am"},{"key":"BF3302199_CR3","first-page":"5241","volume-title":"Metabolic and Molecular Basis of Inherited Diseases","author":"PH Byres","year":"2001","unstructured":"Byres PH . Disorders of collagen biosynthesis and structure. In: Scriver CR, Beaudet A, Sly WS, Valle D (eds). Metabolic and Molecular Basis of Inherited Diseases. McGraw Hill: New York, Vol. IV, 8th edn. 2001, pp 5241\u20135285."},{"key":"BF3302199_CR4","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1096\/fasebj.5.7.2010058","volume":"5","author":"H Kuivanieni","year":"1991","unstructured":"Kuivanieni H, Tromp G, Prockop DJ . Mutations in collagen genes: causes of rare and some common diseases in humans. FASEB J 1991; 5: 2052\u20132060.","journal-title":"FASEB J"},{"key":"BF3302199_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0934-8832(11)80085-5","volume":"12","author":"PH Byres","year":"1992","unstructured":"Byres PH, Pyritz RE, Uitto J . Research perspectives of inheritable disorders of connective tissues. Matrix 1992; 12: 333\u2013342.","journal-title":"Matrix"},{"key":"BF3302199_CR6","first-page":"49","volume-title":"Collagen. Vol. 5. Pathobiochemistry","author":"JR Shapiro","year":"1992","unstructured":"Shapiro JR, Chipman SD . Osteogenesis imperfecta. In: Kang A, Nimni ME (eds). Collagen. Vol. 5. Pathobiochemistry. CRC Press: Boca Raton, FL, 1992, pp 49\u201385."},{"key":"BF3302199_CR7","unstructured":"Seedorf KS . Osteogenesis imperfecta: a clinical study of clinical features heredity based on 55 Danish families, Universitetsforlaget I, Aarthus, 1949."},{"key":"BF3302199_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM . Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16: 101\u2013106.","journal-title":"J Med Genet"},{"key":"BF3302199_CR9","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","volume":"15","author":"FH Glorieux","year":"19200","unstructured":"Glorieux FH et al. Type V osteogenesis imperfecta; a new form of brittle bone disease. J Bone Miner Res 200; 15: 1650\u20131658.","journal-title":"J Bone Miner Res"},{"key":"BF3302199_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","volume":"17","author":"FH Glorieux","year":"2002","unstructured":"Glorieux FH et al. Type VI osteogenesis imperfecta: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002; 17: 30\u201338.","journal-title":"J Bone Miner Res"},{"key":"BF3302199_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S8756-3282(02)00790-1","volume":"31","author":"LM Ward","year":"2002","unstructured":"Ward LM et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002; 31: 12\u201318.","journal-title":"Bone"},{"key":"BF3302199_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1172\/JCI112012","volume":"76","author":"DW Rowe","year":"1985","unstructured":"Rowe DW et al. Diminished type I collagen synthesis and reduced \u03b1(I) collagen mRNA in cultured fibroblasts from patients with dominantly inherited osteogenesis imperfecta. J Clin Invest 1985; 76: 604.","journal-title":"J Clin Invest"},{"key":"BF3302199_CR13","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1073\/pnas.78.8.5142","volume":"78","author":"GS Barsh","year":"1981","unstructured":"Barsh GS, Byers PH . Reduced secretion of structurally abnormal type I procollagen in a form of osteogenesis imperfecta. Proc Natl Acad Sci USA 1981; 78: 5142\u20135146.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302199_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1056\/NEJM199202203260807","volume":"326","author":"DJ Prockop","year":"1992","unstructured":"Prockop DJ . Mutations in collagen genes as a cause of connective tissue diseases. New Engl J Med 1992; 326: 540\u2013546.","journal-title":"New Engl J Med"},{"key":"BF3302199_CR15","doi-asserted-by":"crossref","first-page":"23108","DOI":"10.1016\/S0021-9258(18)50063-6","volume":"25","author":"C Niyibizi","year":"1992","unstructured":"Niyibizi C et al. Incorporation level of a mutant collagen \u03b12(I) chain (Gly580-ASP) into bone matrix in a lethal case of osteogenesis imperfecta. J Biol Chem 1992; 25: 23108\u201323112.","journal-title":"J Biol Chem"},{"key":"BF3302199_CR16","first-page":"S489","volume":"1993","author":"DJ Prockop","year":"202","unstructured":"Prockop DJ et al. Mutations in type 1 procollagen that cause osteogenesis imperfecta: effects of the mutations on the assembly of collagen into fibrils, the basis of phenotypic variations, and potential antisense therapies. J Bone Miner Res suppl 2; 1993: S489\u2013S492.","journal-title":"J Bone Miner Res suppl"},{"key":"BF3302199_CR17","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1096\/fasebj.5.13.1916105","volume":"5","author":"M van der Rest","year":"1991","unstructured":"van der Rest M, Garrone R . Collagen family of proteins. FASEB J 1991; 5: 2814\u20132823.","journal-title":"FASEB J"},{"key":"BF3302199_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1432-1033.1994.00943.x","volume":"224","author":"C Niyibizi","year":"1994","unstructured":"Niyibizi C, Eyre D . Structural characteristics of cross-linking sites in type V collagen of bone chain specificities and heterotypic links to type I collagen. Eur J Biochem 1994; 224: 943\u2013950.","journal-title":"Eur J Biochem"},{"key":"BF3302199_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/(SICI)1096-8628(19960503)63:1<167::AID-AJMG29>3.0.CO;2-L","volume":"63","author":"AA Culbert","year":"1996","unstructured":"Culbert AA, Kadler KE . Tracing the pathway between mutation and phenotype in OI; isolation of mineralization of specific genes. Am J Med Genet 1996; 63: 167\u2013174.","journal-title":"Am J Med Genet"},{"key":"BF3302199_CR20","first-page":"11","volume":"159","author":"DO Sillence","year":"1989","unstructured":"Sillence DO . Osteogenesis imperfecta: an expanding panorama of variants. Clin Orthop Rel Res 1989; 159: 11\u201325.","journal-title":"Clin Orthop Rel Res"},{"key":"BF3302199_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/01241398-199103000-00012","volume":"11","author":"S Porat","year":"1991","unstructured":"Porat S, Heller E, Seidamamn DS . Functional results of operations in OI: elongating and nonelongating rods with pediatric orthopaedics. J Pediatr Orthop 1991; 11: 200\u2013203.","journal-title":"J Pediatr Orthop"},{"key":"BF3302199_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0022-3476(96)70077-X","volume":"129","author":"F Antoniazzi","year":"1996","unstructured":"Antoniazzi F et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 1996; 129: 432\u2013439.","journal-title":"J Pediatr"},{"key":"BF3302199_CR23","first-page":"251","volume":"76","author":"JC Marini","year":"1993","unstructured":"Marini JC et al. The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. J Clin Endocrinol Metab 1993; 76: 251\u2013256.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF3302199_CR24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947\u2013952.","journal-title":"N Engl J Med"},{"key":"BF3302199_CR25","first-page":"1846","volume":"85","author":"H Plotkin","year":"2000","unstructured":"Plotkin H et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85: 1846\u20131850.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF3302199_CR26","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1172\/JCI0215952","volume":"110","author":"F Rauch","year":"2002","unstructured":"Rauch F et al. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110: 1293\u20131299.","journal-title":"J Clin Invest"},{"key":"BF3302199_CR27","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","volume":"289","author":"GA Rodan","year":"2000","unstructured":"Rodan GA, Martin TJ . Therapeutic approaches to bone diseases. Science 2000; 289: 1508\u20131514.","journal-title":"Science"},{"key":"BF3302199_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s002239900670","volume":"65","author":"C Cepollaro","year":"1999","unstructured":"Cepollaro C et al. Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters. Calcif Tissue Int 1999; 65: 129\u2013132.","journal-title":"Calcif Tissue Int"},{"key":"BF3302199_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1203\/00006450-198303000-00007","volume":"17","author":"R Baron","year":"1983","unstructured":"Baron R et al. Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 1983; 17: 204\u2013207.","journal-title":"Pediatr Res"},{"key":"BF3302199_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s002230010045","volume":"69","author":"NP Camacho","year":"2001","unstructured":"Camacho NP et al. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 2001; 69: 94\u2013101.","journal-title":"Calcif Tissue Int"},{"key":"BF3302199_CR31","first-page":"201","volume":"120","author":"G Gothin","year":"1996","unstructured":"Gothin G, Ericsson JLM . The osteoclast: review of ultrastructure, origin and structure\u2013function relationship. Clin Orthop 1996; 120: 201\u2013231.","journal-title":"Clin Orthop"},{"key":"BF3302199_CR32","first-page":"51","volume-title":"Principals of Bone Biology","author":"J Aubin","year":"1996","unstructured":"Aubin J, Fina L . The osteoblast lineage. In: Bilezekian J, Raisiz L, Rodan GA (eds). Principals of Bone Biology. Academic Press: San Diego, 1996, pp 51\u201368."},{"key":"BF3302199_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1126\/science.276.5309.71","volume":"276","author":"DJ Prockop","year":"1997","unstructured":"Prockop DJ . Marrow stromal cells as stem cells for non-hematopoietic tissues. Science 1997; 276: 71\u201374.","journal-title":"Science"},{"key":"BF3302199_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1126\/science.284.5411.143","volume":"284","author":"MF Pittenger","year":"1999","unstructured":"Pittenger MF et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143\u2013147.","journal-title":"Science"},{"key":"BF3302199_CR35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/jor.1100090504","volume":"9","author":"AI Caplan","year":"1991","unstructured":"Caplan AI . Mesenchymal stem cells. J Orthop Res 1991; 9: 641\u2013650.","journal-title":"J Orthop Res"},{"key":"BF3302199_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0074-7696(08)60092-3","volume":"47","author":"AJ Friedenstein","year":"1976","unstructured":"Friedenstein AJ . Precursor cells of mechanocytes. Int Rev Cytol 1976; 47: 327\u2013359.","journal-title":"Int Rev Cytol"},{"key":"BF3302199_CR37","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1073\/pnas.92.11.4857","volume":"92","author":"RF Pereira","year":"1995","unstructured":"Pereira RF et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage and lung in irradiated mice. Proc Natl Acad Sci USA 1995; 92: 4857\u20134861.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302199_CR38","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1073\/pnas.95.3.1142","volume":"95","author":"RF Pereira","year":"1988","unstructured":"Pereira RF et al. Marrow stromal cells as a source of progenitor cells for non hematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci USA 1988; 95: 1142\u20131147.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302199_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/sj.gt.3300839","volume":"6","author":"M Oyama","year":"1999","unstructured":"Oyama M et al. Retrovirally transduced bone marrow stromal cells isolated from a mouse model of human osteogenesis imperfecta (oim) persist in bone and retain the ability to form cartilage and bone after extended passaging. Gene Therapy 1999; 6: 321\u2013329.","journal-title":"Gene Therapy"},{"key":"BF3302199_CR40","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1084\/jem.189.4.729","volume":"189","author":"SK Nilsson","year":"1999","unstructured":"Nilsson SK et al. Cells capable of bone production engraft from whole bone marrow transplants in non-ablated mice. J Exp Med 1999; 189: 729\u2013734.","journal-title":"J Exp Med"},{"key":"BF3302199_CR41","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0301-472X(00)00635-4","volume":"29","author":"S Devinem","year":"2001","unstructured":"Devinem S et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29: 244\u2013255.","journal-title":"Exp Hematol"},{"key":"BF3302199_CR42","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/81395","volume":"6","author":"KW Liechty","year":"2000","unstructured":"Liechty KW et al. Human mesenchymal stem cells engraft and demonstrate site specific differentiation after in utero transplantation in sheep. Nat Med 2000; 6: 1282\u20131286.","journal-title":"Nat Med"},{"key":"BF3302199_CR43","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/00003086-200010001-00017","volume":"379S","author":"C Niyibzi","year":"2000","unstructured":"Niyibzi C et al. Potential of gene therapy for treating osteogenesis imperfecta. Clin Orthop Rel Res 2000; 379S: 126\u2013133.","journal-title":"Clin Orthop Rel Res"},{"key":"BF3302199_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/6529","volume":"5","author":"EM Horwitz","year":"1999","unstructured":"Horwitz EM et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal stem cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309\u2013313.","journal-title":"Nat Med"},{"key":"BF3302199_CR45","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1182\/blood.V97.5.1227","volume":"97","author":"EM Horwitz","year":"2001","unstructured":"Horwitz EM et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001; 97: 1227\u20131231.","journal-title":"Blood"},{"key":"BF3302199_CR46","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1073\/pnas.132252399","volume":"25","author":"EM Horwitz","year":"2002","unstructured":"Horwitz EM et al. Isolated allogeneic bone marrow-derived mesenchymal stem cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 25: 8932\u20138937.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302199_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1006\/mgme.2000.3039","volume":"71","author":"A Forlino","year":"2000","unstructured":"Forlino A, Marini JC . Osteogenesis imperfecta: prospects for molecular therapeutics. Mol Genet Metab 2000; 71: 225\u2013232.","journal-title":"Mol Genet Metab"},{"key":"BF3302199_CR48","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1093\/hmg\/11.19.2201","volume":"11","author":"S Millington-Ward","year":"2002","unstructured":"Millington-Ward S et al. Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta. Hum Mol Genet 2002; 11: 2201\u20132206.","journal-title":"Hum Mol Genet"},{"key":"BF3302199_CR49","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/oli.1.1999.9.537","volume":"9","author":"S Millington-Ward","year":"1999","unstructured":"Millington-Ward S et al. A mutation-independent therapeutic strategem for osteogenesis imperfecta. Antisense Nucleic Acid Drug Dev 1999; 9: 537\u2013542.","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"BF3302199_CR50","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/hmg\/6.9.1415","volume":"6","author":"S Millington-Ward","year":"1997","unstructured":"Millington-Ward S et al. Strategems in vitro for gene therapies directed to dominant mutations. Hum Mol Genet 1997; 6: 1415\u20131426.","journal-title":"Hum Mol Genet"},{"key":"BF3302199_CR51","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.1997.03540330068037","volume":"277","author":"JC Marini","year":"1997","unstructured":"Marini JC, Gerber NL . Osteogenesis imperfecta rehabilitation and prospects for gene therapy. JAMA 1997; 277: 746\u2013750.","journal-title":"JAMA"},{"key":"BF3302199_CR52","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1073\/pnas.91.14.6298","volume":"91","author":"S Jaspal","year":"1994","unstructured":"Jaspal S, Hillan SL, Prockop DJ . Partial rescue of a lethal phenotype of fragile bones in transgenic mice with a chimeric antisense gene directed against a mutated collagen gene. Proc Natl Acad Sci USA 1994; 91: 6298\u20136302.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302199_CR53","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1172\/JCI118434","volume":"97","author":"Q Wang","year":"1996","unstructured":"Wang Q, Marini JC . Antisense oligodeoxynucleotides selectively suppress expression of the mutant \u03b11(I) collagen allele in Type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. J Clin Invest 1996; 97: 448\u2013454.","journal-title":"J Clin Invest"},{"key":"BF3302199_CR54","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3109\/07853899608999114","volume":"28","author":"G Grassi","year":"1996","unstructured":"Grassi G, Marini JC . Ribozymes: structure, function, and potential therapy for dominant genetic disorders. Ann Med 1996; 28: 499\u2013510.","journal-title":"Ann Med"},{"key":"BF3302199_CR55","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1093\/nar\/28.20.4013","volume":"28","author":"PA Dawson","year":"2000","unstructured":"Dawson PA, Marini JC . Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts. Nucleic Acids Res 2000; 28: 4013\u20134020.","journal-title":"Nucleic Acids Res"},{"key":"BF3302199_CR56","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1093\/nar\/25.17.3451","volume":"25","author":"G Grassi","year":"1997","unstructured":"Grassi G, Forlino A, Marini JC . Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects. Nucleic Acids Res 1997; 25: 3451\u20133458.","journal-title":"Nucleic Acids Res"},{"key":"BF3302199_CR57","doi-asserted-by":"publisher","first-page":"9742","DOI":"10.1073\/pnas.171251798","volume":"98","author":"NJ Caplen","year":"2001","unstructured":"Caplen NJ et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001; 98: 9742\u20139747.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302199_CR58","unstructured":"Allen D et al. Development of RNAi as a mutation independent gene therapy for osteogenesis imperfecta. Abstract presented at the 8th International Conference of Osteogenesis Imperfecta, Annecy, France, 2002."},{"key":"BF3302199_CR59","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1073\/pnas.90.5.1701","volume":"90","author":"SD Chipman","year":"1993","unstructured":"Chipman SD et al. Defective pro\u03b12(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc Natl Acad USA 1993; 90: 1701\u20131705.","journal-title":"Proc Natl Acad USA"},{"key":"BF3302199_CR60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/096368970000900303","volume":"9","author":"K Suzuki","year":"2000","unstructured":"Suzuki K et al. In vivo expression of human growth hormone by genetically modified murine bone marrow stromal cells and its effect on the cells in vitro. Cell Transplant 2000; 9: 319\u2013327.","journal-title":"Cell Transplant"},{"key":"BF3302199_CR61","first-page":"328","volume":"49","author":"MS Sands","year":"1999","unstructured":"Sands MS, Baker JE . Percutaneous intravenous injection in neonatal mice. Lab Anim Sci 1999; 49: 328\u2013330.","journal-title":"Lab Anim Sci"},{"key":"BF3302199_CR62","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/jcb.1209","volume":"83","author":"C Niyibizi","year":"2001","unstructured":"Niyibizi C et al. Transfer of proalpha2(I) cDNA into cells of a murine model of human osteogenesis imperfecta restores synthesis of type I collagen comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and in vivo. J Cell Biochem 2001; 83: 84\u201391.","journal-title":"J Cell Biochem"},{"key":"BF3302199_CR63","doi-asserted-by":"publisher","first-page":"7294","DOI":"10.1073\/pnas.96.13.7294","volume":"96","author":"Z Hou","year":"1999","unstructured":"Hou Z et al. Osteoblast-specific gene expression after transplantation of marrow cells: implications for skeletal gene therapy. Proc Natl Acad Sci USA 1999; 96: 7294\u20137299.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302199_CR64","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0092-8674(00)80257-3","volume":"89","author":"P Ducy","year":"1997","unstructured":"Ducy P et al. Osf2\/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747\u2013754.","journal-title":"Cell"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/3302199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/3302199","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/3302199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T02:17:35Z","timestamp":1648606655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/3302199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,15]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,2,1]]}},"alternative-id":["BF3302199"],"URL":"https:\/\/doi.org\/10.1038\/sj.gt.3302199","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,15]]},"assertion":[{"value":"15 January 2004","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}